Biocon Biologics to introduce three new oncology biosimilars, eyes $75 billion market opportunity
The new assets expand Biocon Biologics’ already robust oncology portfolio, which now includes 17 cancer therapies
The new assets expand Biocon Biologics’ already robust oncology portfolio, which now includes 17 cancer therapies
The trial aims to measure AF burden—the percentage of time patients spend in arrhythmia—as its primary efficacy endpoint
India should explore Sustainability-Linked Incentives (SLI) targeting innovations in the 12 principles of green chemistry
India’s pharmaceutical sector stands at a pivotal inflection point
The company is pursuing the accelerated FDA 505(b)(2) approval pathway for its once-daily oral ondansetron formulation
Under the agreement, Insilico could receive up to $32 million in upfront and near-term R&D payments
Valneva said regaining full rights to the vaccine will allow the company to “assume direct control over its supply chain and commercialization for endemic high-risk countries
Pembrolizumab has shown meaningful benefit only when combined with chemotherapy
The study will run across 18 sites and enroll roughly 200 patients over 24 months
Motiva, SmoothSilk, Round and Ergonomix implants represent the latest in plastic surgery innovation
Subscribe To Our Newsletter & Stay Updated